Gluten-Free Hope for Celiac
Initial experimental results for the drug ANP 033, which aims to reduce intestinal damage and symptoms of celiac disease, showed that patients who took the medication before gluten exposure experienced less damage and fewer symptoms compared to the placebo group. The study included 32 patients, of whom 17 received the drug and 15 received a placebo. Notable differences were observed in the need for symptom relief medications, with only 6% of those on the drug requiring them compared to 47% in the other group. However, these findings are still early, and experts emphasize that adhering to a gluten-free diet remains the primary treatment for celiac disease until the safety and efficacy of this drug can be confirmed on a larger scale.
Notice: This Is an AI-Generated Summary
Comments (0)